The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R03 | Drugs for obstructive airway diseases | |
| 3 | R03D | Other systemic drugs for obstructive airway diseases | |
| 4 | R03DC | Leukotriene receptor antagonists | |
| 5 | R03DC03 | Montelukast |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 10 mg |
| Active Ingredient | Description | |
|---|---|---|
| Montelukast |
Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. ฮคhe CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| MONKASTA Film-coated tablet | Medicines Authority (MT) | MPI, EU: SmPC | |
| SINGULAIR Tablet / Chewable Tablet / Granule | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
